Q-omics provides the consensus-scored DAB2IP profile across patient tissues and cancer cell-line models. DAB2IP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DAB2IP is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, DAB2IP protein abundance shows 23,610 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where DAB2IP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DAB2IP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DAB2IP survival associations across molecular data types. DAB2IP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DAB2IP RNA expression–survival associations across cancer types. High DAB2IP expression shows unfavorable associations in HNSC and LUSC, but favorable associations in KIRC, KIRP, STAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DAB2IP RNA expression.
This table summarizes DAB2IP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DAB2IP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DAB2IP shows lower tumor expression in LUAD, COAD and BLCA and higher tumor expression in HNSC, THCA and LIHC. The HNSC box plot shows higher DAB2IP RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with DAB2IP in patient tissues and cancer cell lines. In patient samples, DAB2IP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DAB2IP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
